<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NEOMYCIN AND POLYMYXIN B SULFATES, AND BACITRACIN ZINC- neomycin sulfate, polymyxin b sulfate and bacitracin zinc ointment </strong><br>Henry Schein Inc.<br></p></div>
<h1>Neomycin and Polymyxin B Sulfates and<br>Bacitracin Zinc Ophthalmic Ointment, USP
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">Rx only
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:
</h1>
<p class="First">Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment, USP is a sterile antimicrobial ointment for ophthalmic use. Each gram contains: Neomycin Sulfate (equivalent to 3.5 mg neomycin base), Polymyxin B sulfate equal to 10,000 polymyxin B units, bacitracin zinc equal to 400 bacitracin units, and white petrolatum, q.s.
</p>
<p>Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of <span class="Italics">Streptomyces fradiae</span> Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 mcg of neomycin standard per mg, calculated on an anhydrous basis. The structural formula are:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Neomycin Sulfate Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=02af2a5f-32fb-460b-b29f-7b18cb95204c&amp;name=neo07-0000-01.jpg">
</div>
<p>Polymyxin B sulfate is the sulfate salt of polymyxin B<span class="Sub">1</span> and B<span class="Sub">2</span> , which are produced by the growth of <span class="Italics">Bacillus polymyxa</span> (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are:
</p>
<div class="Figure">
<a name="f02"></a><img alt="Polymyxin B Sulfate Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=02af2a5f-32fb-460b-b29f-7b18cb95204c&amp;name=neo07-0000-02.jpg">
</div>
<p>Bacitracin zinc is the zinc salt of bacitracin, a mixture of related cyclic polypeptides (mainly bacitracin A) produced by the growth of an organism of the <span class="Italics">licheniformis</span> group of <span class="Italics">Bacillus subtilis</span> var Tracy. It has a potency of not less than 40 bacitracin units per mg. The structural formula is:
</p>
<div class="Figure">
<a name="f03"></a><img alt="Bacitracin Zinc Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=02af2a5f-32fb-460b-b29f-7b18cb95204c&amp;name=neo07-0000-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">A wide range of antibacterial action is provided by the overlapping spectra of neomycin, polymyxin B sulfate, and bacitracin.
</p>
<p>Neomycin is bactericidal for many gram-positive and gram-negative organisms. It is an aminoglycoside antibiotic, which inhibits protein synthesis by binding with ribosomal RNA and causing misreading of the bacterial genetic code.
</p>
<p>Polymyxin B is bactericidal for a variety of gram-negative organisms. It increases the permeability of the bacterial cell membrane by interacting with the phospholipid components of the membrane.
</p>
<p>Bacitracin is bactericidal for a variety of gram-positive and gram-negative organisms. It interferes with bacterial cell wall synthesis by inhibition of the regeneration of phospholipid receptors involved in peptidoglycan synthesis.
</p>
<div class="Section" data-sectionCode="49489-8">
<a name="s4"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold">Microbiology:</span> Neomycin sulfate, polymyxin B sulfate, and bacitracin zinc together are considered active against the following microorganisms: Staphylococcus aureus, streptococci including Streptococcus pneumoniae, Escherichiacoli, Haemophilusinfluenzae, Klebsiella/ Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. The product does not provide adequate coverage against Serratia marcescens.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s5"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment. USP is indicated for the topical treatment of superficial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the external eye and its adnexa caused by susceptible bacteria. Such <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> encompass <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> and <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratoconjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span> and <span class="product-label-link" type="condition" conceptid="374347" conceptname="Blepharoconjunctivitis">blepharoconjunctivitis</span>.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s6"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment, USP is contraindicated in individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s7"></a><a name="section-6"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First">NOT FOR INJECTION INTO THE EYE. Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ointment, USP should never be directly introduced into the anterior chamber of the eye. Ophthalmic ointments may retard corneal <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.
</p>
<p>Topical antibiotics, particularly neomycin sulfate, may cause cutaneous sensitization. A precise incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (primarily <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>) due to topical antibiotics is not known. The manifestations of sensitization to topical antibiotics are usually <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, reddening, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the conjunctiva and eyelid. A sensitization reaction may manifest simply as a failure to heal. During long-term use of topical antibiotic products, periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. Symptoms usually subside quickly on withdrawing the medication. Application of products containing these ingredients should be avoided for the patient thereafter (see <a href="#s9">PRECAUTIONS: General</a>).
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s8"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s9"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">General:</span> As with other antibiotic preparations, prolonged use of Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment, USP may result in overgrowth of nonsusceptible organisms including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, appropriate measures should be initiated.
</p>
<p><span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">Bacterial resistance</span> to Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment, USP may also develop. If <span class="product-label-link" type="condition" conceptid="4145093" conceptname="Purulent discharge">purulent discharge</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> becomes aggravated, the patient should discontinue use of the medication and consult a physician.
</p>
<p>There have been reports of bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> associated with the use of topical ophthalmic products in multiple-dose containers, which have been inadvertently contaminated by patients, most of whom had a concurrent corneal disease or a disruption of the ocular epithelial surface (see <a href="#s10">PRECAUTIONS: Information for Patients</a>).
</p>
<p>Allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: kanamycin, paromomycin, streptomycin, and possibly gentamicin.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s10"></a><a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold">Information for Patients:</span> Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, eyelid, fingers, or any other surface. The use of this product by more than one person may spread <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.
</p>
<p>Patients should also be instructed that ocular products, if handled improperly, can become contaminated by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated products (see <a href="#s9">PRECAUTIONS: General</a>).
</p>
<p>If the condition persists or gets worse, or if a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or allergic action develops, the patient should be advised to stop use and consult a physician, Do not use this product if you are allergic to any of the listed ingredients.
</p>
<p>Keep tightly closed when not in use. Keep out of reach of children.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s11"></a><a name="section-7.3"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span> Long term studies in animals to evaluate carcinogenic or mutagenic potential have not been conducted with polymyxin B sulfate or bacitracin. Treatment of cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> in vitro with neomycin increased the frequency of chromosome aberrations at the highest concentration (80 mcg/mL) tested; however, the effects of neomycin on carcinogenesis and mutagenesis in humans are unknown.
</p>
<p>Polymyxin B has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown. No adverse effects on male or female fertility, liter size or survival were observed in rabbits given bacitracin zinc 100 gm/ton of diet.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s12"></a><a name="section-7.4"></a><p></p>
<p class="First"><span class="Bold">Pregnancy: Teratogenic Effects:</span> Pregnancy Category C. Animal reproduction studies have not been conducted with neomycin sulfate, polymyxin B sulfate, or bacitracin. It is also not known whether Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment, USP should be given to pregnant woman only if clearly needed.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s13"></a><a name="section-7.5"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span> It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment, USP is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s14"></a><a name="section-7.6"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span> Safety and effectiveness in pediatric patients have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s15"></a><a name="section-7.7"></a><p></p>
<p class="First"><span class="Bold">Geriatric Use:</span> No overall differences in safety or effectiveness have been observed between elderly and younger patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s16"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">Adverse reactions have occurred with the anti-infective components of Neomycin and Polymyxin B Sulfate and Bacitracin Zinc Ophthalmic Ointment, USP. The exact incidence is not known. Reactions occurring most often are allergic sensitization reactions including <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and conjunctival <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (see <a href="#s7">WARNINGS</a>). More serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have been reported rarely.
</p>
<p>Local irritation on instillation has also been reported.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s17"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Apply the ointment every 3 or 4 hours for 7 to 10 days, depending on the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s18"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">Tube of 1/8 oz. (3.5 g) with ophthalmic tip.
</p>
<p>NDC 0404-7194-01
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s19"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span> Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
</p>
<p>Distributed by (in US only):<br><span class="Bold">HENRY SCHEIN INC.<br></span>135 DURYEA ROAD<br>MELVILLE, NY 11747 USA
</p>
<p>BNPB00N Rev. 08/14
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s20"></a><a name="section-11"></a><p></p>
<p class="First">Principal Display Panel Text for Container Label:
</p>
<p>HENRY SCHEIN Logo
</p>
<p>NDC 0404-7194-01
</p>
<p>112-7194
</p>
<p>NEOMYCIN AND POLYMYXIN B SULFATES AND
</p>
<p>BACITRACIN ZINC OPHTHALMIC OINTMENT, USP
</p>
<p>Sterile Ophthalmic Ointment
</p>
<p>Rx only Net Wt. 3.5 g (1/8 oz.)
</p>
<div class="Figure">
<a name="f04"></a><img alt="Principal Display Panel Text for Container Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=02af2a5f-32fb-460b-b29f-7b18cb95204c&amp;name=neo07-0000-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s21"></a><a name="section-12"></a><p></p>
<p class="First">Principal Display Panel Text for Carton Label:
</p>
<p>HENRY SCHEIN Logo
</p>
<p>NDC 0404-7194-01
</p>
<p>112-7194
</p>
<p>NEOMYCIN AND POLYMYXIN B SULFATES AND
</p>
<p>BACITRACIN ZINC OPHTHALMIC OINTMENT, USP
</p>
<p>Sterile Ophthalmic Ointment      Rx only Net Wt. 3.5 g (1/8 oz.)
</p>
<p>HENRY SCHEIN Ribbon Seal
</p>
<div class="Figure">
<a name="f05"></a><img alt="Principal Display Panel Text for Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=02af2a5f-32fb-460b-b29f-7b18cb95204c&amp;name=neo07-0000-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NEOMYCIN AND POLYMYXIN B SULFATES, AND BACITRACIN ZINC 		
					</strong><br><span class="contentTableReg">neomycin sulfate, polymyxin b sulfate and bacitracin zinc ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0404-7194</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Neomycin Sulfate</strong> (Neomycin) </td>
<td class="formItem">Neomycin</td>
<td class="formItem">3.5 mg  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Polymyxin B Sulfate</strong> (Polymyxin B) </td>
<td class="formItem">Polymyxin B</td>
<td class="formItem">10000 [USP'U]  in 1 g</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Bacitracin Zinc</strong> (Bacitracin) </td>
<td class="formItem">Bacitracin</td>
<td class="formItem">400 [USP'U]  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Petrolatum</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0404-7194-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3.5 g in 1 TUBE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065088</td>
<td class="formItem">05/13/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Henry Schein Inc.
							(012430880)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>71844925-a2c1-43e6-be95-09244f3fe524</div>
<div>Set id: 02af2a5f-32fb-460b-b29f-7b18cb95204c</div>
<div>Version: 1</div>
<div>Effective Time: 20150513</div>
</div>
</div> <div class="DistributorName">Henry Schein Inc.</div></p>
</body></html>
